Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Avalo Therapeutics Inc (AVTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.07-2.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AVTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash runway into 2029 | A supporting condition in Avalo Therapeutics Inc's published investment case. The stated target is Cash reserves to extend into 2029. | Intact | Cash runway projected to fall short of 2029 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Update: • Cash, cash equivalents and investments were $472.2 million as of June 30, 2026.” “Avalo’s current cash, cash equivalents, and investments are expected to fund operations into 2029.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, where the business case depends on developing medicines rather than established earnings. The long-term thesis is in a watch state: abdakibart is progressing toward a planned Phase 3 program, but recent performance is weak and overall evidence confidence is low.
The valuation model indicates AVTX trades at a 5.25% premium to peers, with pipeline optionality, or potential future value from development programs, cited as the main reason. Model confidence is low, and the evidence does not specify what investors already assume about clinical success, so the expectations gap is unclear.
Near term, results and execution remain uncertain: AVTX had an earnings miss in August, and the next report carries elevated miss risk. Over the multi-year view, management is progressing abdakibart toward a planned Phase 3 start in the first half of 2027 and expects its cash runway to extend into 2029; AVTX-010 is at an earlier stage, with an IND submission planned for the first half of 2027.
The thesis hinges on advancing abdakibart into Phase 3 and delivering credible progress on AVTX-010, while maintaining enough cash to support development. Near term, weaker guidance or further weak results would add concern; stronger Healthcare-sector earnings could help the sector backdrop, but would not resolve AVTX’s clinical execution risk.
Over the next 1 to 3 years, AVTX remains a high-risk, early-stage development story with improved cash support but limited evidence of financial strength. The multi-year view depends mainly on clinical progress and disciplined use of capital. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Initiate Phase 3 trial for abdakibart | They plan to initiate a Phase 3 trial for abdakibart in hidradenitis suppurativa in the first half of 2027. | Intact | Phase 3 trial not initiated by H1 2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Recent Corporate Highlights and Upcoming Anticipated Milestones • Avalo plans to initiate a registrational Phase 3 program evaluating abdakibart in HS in the first half of 2027.” “The trial successfully met its primary endpoint at both doses studied (p=0.018 150mg, p=0.015 300mg and p=0.004, combined), demonstrating a 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16, respectively (42.5% combined; placebo rate 25.6%).” Delivery assessment Nov 4, 2026 |
Advance AVTX-010 development | A supporting condition in Avalo Therapeutics Inc's published investment case. The stated target is IND submission for AVTX-010 planned for H1 2027. | Intact | IND submission not made by H1 2027 | IND submission planned H1 2027 vs target H1 2027 News covers CFO sales and analyst cuts; no reports of clinical trial delays or missed IND timelines. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “The Company expects to submit an Investigational New Drug (IND) application in the first half of 2027.” “The Company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027.” Delivery assessment Nov 4, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.76 → $-2.91 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.76 | $0 | 11 / 12 |
| 2026-07-25 | $-2.76 | $0 | 11 / 12 |
| 2026-07-26 | $-2.76 | $0 | 11 / 12 |
| 2026-07-27 | $-2.76 | $0 | 11 / 12 |
| 2026-07-28 | $-2.76 | $0 | 11 / 12 |
| 2026-07-29 | $-2.76 | $0 | 11 / 12 |
| 2026-07-30 | $-2.76 | $0 | 11 / 12 |
| 2026-07-31 | $-2.76 | $0 | 11 / 12 |
| 2026-08-01 | $-2.99 | $1,000,000 | 11 / 12 |
| 2026-08-02 | $-2.76 | $0 | 11 / 12 |
| 2026-08-03 | $-2.76 | $0 | 11 / 12 |
| 2026-08-04 | $-2.76 | $0 | 11 / 12 |
| 2026-08-05 | $-2.76 | $0 | 11 / 12 |
| 2026-08-06 | $-2.76 | $0 | 11 / 12 |
| 2026-08-07 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-08 | $-2.76 | $0 | 11 / 12 |
| 2026-08-09 | $-2.76 | $0 | 11 / 12 |
| 2026-08-10 | $-2.76 | $0 | 11 / 12 |
| 2026-08-11 | $-2.74 | $0 | 11 / 12 |
| 2026-08-12 | $-2.74 | $0 | 11 / 12 |
| 2026-08-13 | $-2.63 | $0 | 10 / 13 |
| 2026-08-14 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-15 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-16 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-17 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-18 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-19 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-20 | $-3.14 | $1,000,000 | 11 / 12 |
| 2026-08-21 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-22 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-23 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-24 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-25 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-26 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-27 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-28 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-29 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-30 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-08-31 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-09-01 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-09-02 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-09-03 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-09-04 | $-2.88 | $1,000,000 | 11 / 13 |
| 2026-09-05 | $-2.88 | $1,000,000 | 10 / 13 |
| 2026-09-06 | $-2.88 | $1,000,000 | 10 / 13 |
| 2026-09-07 | $-2.88 | $1,000,000 | 10 / 12 |
| 2026-09-08 | $-2.88 | $1,000,000 | 10 / 12 |
| 2026-09-09 | $-2.88 | $1,000,000 | 10 / 12 |
| 2026-09-10 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-11 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-12 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-13 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-14 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-15 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-16 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-17 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-18 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-19 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-20 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-21 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-22 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-23 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-24 | $-2.98 | $1,000,000 | 10 / 12 |
| 2026-09-25 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-09-26 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-09-27 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-09-28 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-09-29 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-09-30 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-01 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-02 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-03 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-04 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-05 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-06 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-07 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-08 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-09 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-10 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-11 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-12 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-13 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-14 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-15 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-16 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-17 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-18 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-19 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-20 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-21 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-22 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-23 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-24 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-25 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-26 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-27 | $-2.98 | $1,000,000 | 9 / 12 |
| 2026-10-28 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-10-29 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-10-30 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-10-31 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-11-01 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-11-02 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-11-03 | $-2.91 | $1,000,000 | 9 / 12 |
| 2026-11-04 | $-2.91 | $1,000,000 | 9 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 4 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.